Glioblastoma with an oligodendroglioma component: Distinct clinical behavior, genetic alterations, and outcome

Neuro-Oncology

Volumn 14, Issue 4, 2012, Pages 518-525

  Wang, Yongzhi ^a   Li, Shouwei ^b   Chen, Lingchao ^c   You, Gan ^a   Bao, Zhaoshi ^a   Yan, Wei ^a   Shi, Zhendong ^d   Chen, Yin ^b   Yao, Kun ^b   Zhang, Wei ^a   Kang, Chunsheng ^d   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

glioblastoma with an oligodendroglioma component; IDH1 mutation; LOH 1p 19q; prognostic; therapeutic response

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; PROTEIN P53; TEMOZOLOMIDE; TENIPOSIDE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SEIZURE;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84859540799     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor232     Document Type: Article

References (20)

1. Kraus JA, Lamszus K, Glesmann N, et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol. 2001;101:311-320. (Pubitemid 32372420)
2. Salvati M, Formichella AI, D'Elia A, et al. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol. 2009;94:129-134.
3. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 2006;65:846-854. (Pubitemid 44371230)
4. Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med. 2007;131:397-406.
5. Louis, DN, Ohgaki, H, Wiestler, OD, et al., eds. World health organization classification of tumours of the central nervous system. Lyon: IARC Press; 2007.
6. Hartmann C, von Deimling A. Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res. 2009;171:25-49.
7. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131:242-251.
8. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol. 2009;11: 737-746.
9. Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology). Neurosurgery. 2010;67: 446-458.
10. Pinto LW, Araujo MB, Vettore AL, et al. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch. 2008;452:481-490.
11. Klink B, Schlingelhof B, Klink M, et al. Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst). 2010;33:37-54.
12. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002-6007.
13. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
14. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol. 2001;60:863-871. (Pubitemid 32880594)
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
16. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003. (Pubitemid 40349502)
17. Lynam LM, Lyons MK, Drazkowski JF, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg. 2007;109:634-638. (Pubitemid 47016762)
18. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
19. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217-223, 23-24.
20. Nakamura H, Makino K, Kuratsu J. Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). Brain Tumor Pathol. 2011;28:185-190.